Experimental Novartis drug shows malaria promise

Posted on 03 September 2010

An experimental Novartis drug can clear malaria infection in mice with a single dose and scientists say it shows promise as a possible future treatment for one of the world’s major killer diseases.
In a study published in the journal Science on Thursday, an international team of scientists said the drug, called NITD609, is effective against [...]

Popularity: 1% [?]

EU Sanctions Merck & Co.’s Sublingual Bipolar Disorder Drug Sycrest

Posted on 03 September 2010

Asenapine therapy was cleared in the U.S. in 2009 to treat schizophrenia and bipolar disorder mania.
Merck & Co’s non-U.S. business, MSD, reported approval throughout the EU for Sycrest®, a sublingual asenapine drug for treating moderate to severe manic episodes in adult patients with bipolar I disorder. Sycrest was first approved in the U.S. in 2009, [...]

Popularity: 1% [?]

Link between bone drugs and oesophageal cancer

Posted on 03 September 2010

The drugs work by strengthening the bones
Long-term use of bone-strengthening drugs – used to treat fractures – may boost the risk of oesophageal cancer, Oxford University research suggests.
The study of 3,000 people found taking bisphosphonates for five years upped the risk from one in 1,000 to two in 1,000 for 60 to 79-year-olds.
The researchers [...]

Popularity: 1% [?]

Allergan inks $600M off-label settlement

Posted on 03 September 2010

Pharma marketing got another black eye yesterday when the Department of Justice announced a $600 million settlement with Allergan. The drugmaker agreed to plead guilty to a misdemeanor and pay a $375 million fine and $225 million in civil penalties, all for pushing Botox for off-label uses such as headache, pain and cerebral palsy treatment.
It’s [...]

Popularity: 1% [?]

See more articles in the archive

Drug Development

Experimental Novartis drug shows malaria promise

Posted on 03 September 2010

An experimental Novartis drug can clear malaria infection in mice with a single dose and scientists say it shows promise as a possible future treatment for one of the world’s major killer diseases.
In a study published in the journal Science on Thursday, an international team of scientists said the drug, called NITD609, is effective against [...]

Popularity: 1% [?]

Neurological Disorders

Puzzles and crosswords delay dementia, study suggests

Posted on 02 September 2010

Could crosswords hold the key to delaying the onset of dementia?
People who do puzzles and crosswords may stave off dementia longer but experience a more rapid decline once the disease sets in, a study suggests.
While there has long been speculation that “exercising” your brain could protect against Alzheimer’s, there has been little evidence to back [...]

Popularity: unranked [?]

News Wire

Allergan inks $600M off-label settlement

Posted on 03 September 2010

Pharma marketing got another black eye yesterday when the Department of Justice announced a $600 million settlement with Allergan. The drugmaker agreed to plead guilty to a misdemeanor and pay a $375 million fine and $225 million in civil penalties, all for pushing Botox for off-label uses such as headache, pain and cerebral palsy treatment.
It’s [...]

Popularity: 1% [?]

Pharma Industry

FDA demands truth-telling plans from Baxter

Posted on 02 September 2010

Don’t pooh-pooh FDA’s warnings on marketing violations. That’s the message Baxter Healthcare got in a recent warning letter. As Pharmalot points out, the letter citing Baxter for mismarketing its lung drug Aralast not only demands that the company stop using the offending brochure, but requires Baxter, as a repeat offender, to come up with a [...]

Popularity: unranked [?]

Site Sponsors